Related Experiment Video

Updated: Jul 13, 2025

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.0K

Liposomal drug formulations for treatment of hematological malignancies

Daniel Cacic Limi1, Håkon Reikvam2,3

  • 1Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway.

Expert Opinion on Pharmacotherapy
|October 12, 2023
PubMed
Abstract

No abstract available in PubMed .

Keywords:
AnthracyclinesHematological malignanciesLiposomal drug formulationTargeted therapy

More Related Videos

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

17.9K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.0K

Related Experiment Videos

Last Updated: Jul 13, 2025

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.0K
Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

17.9K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

Articles linked to this work by shared authors, journal, and citation graph.

A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns.

Journal of blood medicine·2026

Relapse of Acute Myeloid Leukemia With Concomitant Systemic Mastocytosis Five Years Post Allogenic Hematopoietic Stem Cell Transplantation.

Case reports in hematology·2026

Correction: Solberg, A.; Reikvam, H. Iron Status and Physical Performance in Athletes. Life 2023, 13, 2007.

Life (Basel, Switzerland)·2026

NUP214 in Acute Myeloid Leukemia.

Cells·2025

Three-Month Posttransplant Lipidomic Profile Reflects Acute GVHD but Not Chronic GVHD Risk in Allogeneic Stem Cell Recipients.

European journal of haematology·2025

Ferritin in Acute Myeloid Leukemia: Not Only a Marker of Inflammation and Iron Overload, but Also a Regulator of Cellular Iron Metabolism, Signaling and Communication.

International journal of molecular sciences·2025

New and emerging somatostatin therapies for neuroendocrine tumors: "what is in the pipeline".

Expert opinion on pharmacotherapy·2026

Investigating oral blarcamesine for treatment of early Alzheimer's disease.

Expert opinion on pharmacotherapy·2026

Current and new approaches to the treatment landscape for adults with Waldenström macroglobulinemia.

Expert opinion on pharmacotherapy·2026

Management of erythromelalgia: a narrative review and expert opinion.

Expert opinion on pharmacotherapy·2026

Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives.

Expert opinion on pharmacotherapy·2026

Future management of hemophilia a with non-biologic hemostatic agents: a call for precision coagulation.

Expert opinion on pharmacotherapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us